来源：中国新闻网 中新网北京7月9日电 (记者 王东宇)被誉为"CT之眼"的探测器，是该设备最核心的成像部件之一，其精 度直接决定成像质量。近日，在GE医疗北京影像设备制造基地(以下简称"GE医疗北京基地")，迎来了 第3.5万台探测器的正式下线。 工程师正在调试CT设备(GE医疗北京基地供图) 工程师正在调试CT设备(GE医疗北京基地供图) 在CT探测器中，最为关键的部件之一是成像芯片，每个探测器需匹配416个芯片单元，看似相同的芯片 单元因原料晶体生长方向、掺杂均匀性等物理层面的差异，导致每个单元的光电性能会存在微观差异， 若随意拼接会导致成像误差。为此，基地通过AI智能算法，将传统人工匹配需5小时的流程压缩至10分 钟，并从海量成像单元中精准筛选出性能互补的芯片组合，以满足不同型号、不同使用场景的设备需 求，又保证每台设备的成像品质。 因探测器材料对生产环境极其敏感，一粒尘埃都可能导致瑕疵。基地用超过60万次生产经验训练出的 AI质检员，在探测器材料筛选的早期阶段就可提前揪出超90%的原材料质量问题，彻底规避传统制造路 径中因此原因导致的CT成品不通过检测而带来的浪费。(完) 探测器的核心结构包含捕捉X ...

Core Viewpoint - The report highlights Yirui Technology as a leading domestic digital X-ray detector manufacturer, emphasizing its comprehensive product matrix and significant market share in the global landscape [2][5]. Product and Market Position - Yirui Technology has developed over 100 types of digital X-ray detectors, covering various medical and industrial applications, with a shipment increase from 67,000 units in 2021 to 105,500 units in 2023, representing a compound annual growth rate (CAGR) of over 25% [2]. - The company accounted for 20.09% of the global digital X-ray detector shipments in 2023, with a total global shipment forecast of 525,300 units [2]. Business Expansion and Growth Potential - The company is expanding into the core components and overall solutions market, with projected revenue from core components reaching 126 million yuan in 2024, a year-on-year growth of approximately 45.5% [3]. - The overall solutions segment is expected to generate around 96 million yuan in 2024, reflecting a staggering year-on-year growth of 262.56% [3]. - The company has initiated projects for medical DR, C-arm, and CT products, with an anticipated production value of nearly 5 billion yuan by 2030 [3]. Core Component Market Opportunity - The global tube market is projected to grow from $4.26 billion in 2023 to $9.53 billion by 2030, with a CAGR of 12.18% [4]. - Yirui Technology has begun developing various types of tubes since 2022, with some products nearing mass production and achieving international advanced standards [4]. Financial Projections - Revenue forecasts for Yirui Technology are expected to reach 2.266 billion yuan, 3.100 billion yuan, and 4.133 billion yuan for 2025, 2026, and 2027, respectively, with year-on-year growth rates of 23.7%, 36.8%, and 33.3% [5]. - Net profit projections for the same years are 597 million yuan, 790 million yuan, and 1.044 billion yuan, with growth rates of 28.3%, 32.3%, and 32.2% [5].

Investment Rating - The investment rating for the company is "Accumulate" (maintained) [5] Core Views - The company experienced a revenue of 1.83 billion yuan in 2024, a year-over-year decrease of 1.7%, and a net profit attributable to shareholders of 470 million yuan, down 23.4% year-over-year. In Q1 2025, the revenue was 480 million yuan, a decrease of 1.9% year-over-year, while the net profit attributable to shareholders was 140 million yuan, an increase of 2.7% year-over-year [1][2] Performance Summary - In 2024, the company faced pressure on performance due to a slowdown in bidding and fluctuations in demand for new energy testing. However, the company is in a strategic upgrade phase, with ongoing construction projects expected to enhance long-term growth potential. The company is transitioning from a flat detector supplier to a comprehensive imaging solution provider, indicating strong medium to long-term investment value [2][4] - The company launched new medical products, including a 64-row medical CT detector module, and high-end DSA detectors have entered mass production. The new core component business generated revenue of 126 million yuan in 2024, a year-over-year increase of 45.5%, while the comprehensive solutions and technical services business achieved revenue of 86.8 million yuan, a year-over-year increase of 226.3% [2][3] Growth Potential - The company has established overseas sales or customer service platforms in various countries, including the USA, Germany, South Korea, India, Japan, Mexico, Pakistan, Brazil, and South Africa. The company has seen positive growth from major customers, with dental products achieving small batch sales overseas and industrial core components performing well, generating nearly 100 million yuan in revenue [4] - The company is expected to see a gradual recovery in gross margin and a decrease in operating expense ratios as low-margin new products scale up. The operating cash flow for 2024 was 360 million yuan, a year-over-year increase of 5.9% [9][10] Financial Forecasts - The company forecasts revenues of 2.23 billion yuan in 2025, representing a year-over-year growth of 22.01%, and a net profit attributable to shareholders of 599 million yuan, an increase of 28.67% year-over-year. The expected EPS for 2025 is 4.18 yuan, with a current price-to-earnings ratio of 29.7 times [10][12]

导读： 仪器信息网对话滨松固体事业部亚洲区销售经理倉田正樹先生，聆听他与滨松共同成长的故事，探寻这家日本光学企业如何以"光"为纽带，在中国市场书 写了一段关于技术、信任与共赢的传奇。 特别提示 微信公众号机制调整，请点击顶部"仪器信息网" → 右上方"…" → 设为 ★ 星标，否则很可能无法看到我们的推送。 在医疗影像领域，每一束精准的光线都可能成为生命诊断的关键。滨松这家以"光"立命的企业，用几十年的坚守与创新，为中国医疗事业发展 点亮了一盏灯。从1 9 9 7年首台国产CT-C2 0 0 0的诞生到如今高端设备的普及，滨松不仅是医疗领域的技术提供者，更是中国社会进步的深度参 与者和见证者。 近日，仪器信息网对话滨松固体事业部亚洲区销售经理倉田正樹先生，聆听他与滨松共同成长的故事，探寻这家日本光学企业如何以"光"为纽 带，在中国市场书写了一段关于技术、信任与共赢的传奇。 "变化"：倉田正樹基于23年职业生涯的中国市场感悟 倉田正樹的职业生涯始于一次"U型折返"。出生于日本滨松市附近小镇的他，小学和中学都在这里度过，大学时来到东京。2 0 0 2年毕业后，他 选择从东京回到家乡，加入滨松，一直在固体事业部做营 ...

导读： 奕瑞科技2024年度实现营业收入18.31亿元，同比下降1.74%；归属于上市公司股东的净利润为4.65亿元，同比下降23.43%。 特别提示 微信机制调整，点击顶部"仪器信息网" → 右上方"…" → 设为 ★ 星标，否则很可能无法看到我们的推送。 近日，奕瑞电子科技集团股份有限公司（简称：奕瑞科技）正式发布2 0 2 4年度报告。报告显示， 公司全年实现营业收入1 8 . 3 1亿元，同比下降 1 . 7 4%；归属于上市公司股东的净利润为4 . 6 5亿元，同比下降2 3 . 4 3%。 尽管短期业绩承压，但奕瑞科技在技术创新、全球化布局及新业务拓 展方面持续发力，为未来发展奠定了坚实基础。 业绩回顾：短期承压，长期动力不减 2 0 2 4年，全球经济复苏乏力，贸易壁垒加剧，下游需求疲软，奕瑞科技的营收与利润均出现小幅下滑。然而，公司通过加大研发投入、优化供 应链和拓展海外市场，展现了较强的抗风险能力。 报告期内，公司研发投入达3 . 1亿元，占营收比重1 6 . 9 4%， 新增知识产权11 5项，其中发明 专利3 0项，彰显了其技术驱动的核心竞争力。 技术 创新：引领X线技术前沿 奕瑞科技始 ...

证券分析师： 张钰莹 S0350524100004 zhangyy03@ghzq.com.cn [Table_Title] 主业筑底企稳，新技术百花齐放 ——奕瑞科技（688301）科创板公司动态研究 最近一年走势 | 相对沪深 | 表现 300 | | | 2025/04/30 | | --- | --- | --- | --- | --- | | 表现 | | 1M | 3M | 12M | | 奕瑞科技 | | 6.1% | 18.8% | -13.9% | | 沪深 300 | | -3.7% | -1.2% | 4.6% | | 市场数据 | 2025/04/30 | | --- | --- | | 当前价格（元） | 121.01 | | 52 周价格区间（元） | 82.51-223.90 | | 总市值（百万） | 17,312.03 | | 流通市值（百万） | 17,312.03 | | 总股本（万股） | 14,306.28 | | 流通股本（万股） | 14,306.28 | | 日均成交额（百万） | 180.09 | | 近一月换手（%） | 0.00 | 2025 年 05 月 ...

Investment Rating - The report maintains a "Buy" rating for the company, indicating a positive outlook for its stock performance in the next 6-12 months [1][5]. Core Views - The company reported a revenue of 1.831 billion RMB in 2024, a decrease of 1.74% year-on-year, and a net profit of 465 million RMB, down 23.43% year-on-year. In Q1 2025, revenue was 482 million RMB, a decrease of 1.92%, while net profit increased by 2.74% to 143 million RMB [3][8]. - The company plans to distribute a cash dividend of 10.00 RMB for every 10 shares to all shareholders, reflecting its commitment to returning value to investors [3]. - Despite short-term performance pressures due to industry challenges, the company is viewed as a leader in the detector market, with a strong long-term growth potential [3][5]. Summary by Sections Financial Performance - The company’s revenue and net profit for 2024 were 1.831 billion RMB and 465 million RMB, respectively. The projected net profits for 2025-2027 are 680 million RMB, 743 million RMB, and 836 million RMB, with corresponding EPS of 4.75, 5.19, and 5.84 RMB [7][9]. - The company’s EBITDA for 2024 is projected at 472 million RMB, with a significant increase expected in subsequent years [7]. Market Position and Strategy - The company is focusing on increasing R&D investments, with 310 million RMB allocated in 2024, aimed at developing new products such as digital X-ray detectors and various types of industrial detectors [8]. - The company has completed its layout for comprehensive solutions, including key components like high-voltage generators and X-ray sources, with several products entering mass production in 2024 [8]. Valuation Metrics - The company’s projected P/E ratios for 2025, 2026, and 2027 are 25.8, 23.6, and 21.0, respectively, indicating a potential for valuation improvement as earnings grow [5][7]. - The projected dividend per share for 2025 is 1.5 RMB, with a dividend yield of 1.2% [7].

Summary of Yirui Technology Conference Call Company Overview - **Company**: Yirui Technology - **Year**: 2024 - **Industry**: Medical Imaging and Industrial Detection Key Points Financial Performance - **2024 Revenue**: 18.3 billion, a slight decrease of 1.7% year-on-year [2][3] - **Net Profit**: 4.65 billion, down 23.4% year-on-year; Non-recurring net profit: 4.39 billion, down 25.8% year-on-year [3] - **Core Business Growth**: Core components revenue increased by approximately 50% to 1.26 billion; Solutions and technical services revenue surged by about 260% to 960 million [2][3] - **Gross Margin**: 50%, down six percentage points year-on-year due to changes in sales structure, slight price reductions in detectors, production cost fluctuations, and accounting adjustments [2][3] Market Dynamics - **Weak Demand**: Domestic medical, dental, and industrial end markets showed weak demand, leading to a 12% decline in detector business [2][3] - **R&D Investment**: R&D expenses reached 310 million, an increase of 50 million year-on-year, with significant progress in product expansion [2][3] - **2025 Q1 Performance**: Revenue remained stable at 4.8 billion; net profit increased by 2.7% to 1.43 billion; non-recurring net profit decreased by 9.2% [5] Strategic Initiatives - **Response to Tariffs**: Established factories in Korea and the U.S. to mitigate the impact of U.S. tariffs; shifting export orders to these locations [2][7][8] - **Domestic Market Opportunities**: The increase in domestic production due to tariffs is beneficial for the company in the high-end X-ray medical imaging sector [8][9] Product Development - **CT Tube Development**: Completed prototype development for CT tubes, currently in client testing phase; significant progress in CT detector core components [10][11] - **Vertical Integration**: Achieved batch delivery in core components like CT ceramics and PD collimators, enhancing competitiveness [4][14] Future Outlook - **2025 Revenue Growth Target**: Aiming for a 20% revenue growth despite uncertainties in domestic medical policies and market recovery [2][5] - **Market Share Goals**: Current global market share is approximately 20%, with a mid-term target of 50% and a long-term goal of over 70% [17] - **Focus on High-End Products**: Plans to increase market share in high-end products, particularly in the medical imaging sector [17] Challenges and Risks - **Trade Tensions**: U.S.-China trade tensions pose risks but also create opportunities for domestic market growth [8][9] - **Economic Factors**: Economic conditions and geopolitical factors have affected overseas revenue, with expectations for gradual recovery in new projects [16] Additional Insights - **Supply Chain Strategy**: Emphasizing vertical integration to enhance supply chain efficiency and product delivery [4][14] - **Collaboration with Major Clients**: Engaging with large clients to boost brand strength and market share, particularly in high-end medical equipment [17][22] Conclusion Yirui Technology is navigating a challenging market environment with strategic initiatives aimed at growth through innovation, market expansion, and operational efficiency. The company is well-positioned to leverage domestic opportunities while addressing the impacts of international trade dynamics.